Smartshop & Psychedelics News
Latest news about psychedelic science, Dutch drug policy, industry developments, and the smartshop market. Updated automatically from leading sources.
Drug Criminalization: Policy vs Public Health Debate Intensifies
New research questions whether drug criminalization reflects actual harm levels or enforcement patterns, with implications for Dutch smart shop policy.
Read full article
Protecting Yourself from Abuse in Psychedelic Ceremonies
As psychedelic ceremonies gain popularity, the community confronts uncomfortable truths about facilitator misconduct and exploitation during vulnerable altered states.
Training Tomorrow's Psychiatrists for Psychedelic Medicine Era
Medical education must evolve to prepare psychiatrists for the integration of psychedelic-assisted therapies into mainstream mental health treatment.
Psychedelic God Complex: When Trips Turn Into Divine Delusions
Psychedelic experiences can sometimes trigger grandiose delusions including divine identity beliefs, requiring careful understanding of risk factors and harm reduction strategies.
Divine Delusions: When Psychedelic Trips Lead to God Complex
Psychedelic experiences can trigger feelings of divine connection or messianic identity, but experts warn when these beliefs persist beyond the trip, professional help may be needed.
Psychedelic Trips and Divine Delusions: When Users Feel Godlike
Mental health experts explain why psychedelic trips sometimes trigger divine delusions and when these spiritual experiences become concerning for users.
NIDA Director Shifts Stance on Psychedelics After Two Decades
NIDA Director Nora Volkow's two-decade evolution from psychedelic skeptic to evidence-based advocate demonstrates how rigorous science can reshape drug policy perspectives.
NIDA Director Shifts Stance on Psychedelics After Two Decades
NIDA Director Nora Volkow's two-decade evolution on psychedelics reflects growing scientific acceptance of these substances' therapeutic potential.
NIDA Director Nora Volkow Shifts Stance on Psychedelic Research
NIDA Director Nora Volkow's evolving views on psychedelics reflect a broader shift toward evidence-based drug policy and research approaches.
New Psychedelic Therapy Program Targets Journalist Trauma Recovery
A new psychedelic therapy program specifically designed for traumatized journalists marks a significant advancement in occupational mental health treatment.
New Psychedelic Therapy Program Targets Trauma in Media Workers
A new psychedelic therapy program specifically designed for traumatized journalists launches, offering hope for media workers suffering from occupational PTSD and complex trauma.
Trauma Therapy Using Psychedelics Now Available for Journalists
A new psychedelic therapy program specifically designed for journalists offers hope for treating trauma-related mental health conditions in media professionals.
Trauma-Focused Psychedelic Therapy Expands to Media Professionals
A new program offers specialized psychedelic-assisted therapy to journalists dealing with trauma, expanding therapeutic applications beyond traditional clinical settings.
Oregon Releases Final 2025 Psilocybin Program Data Report
Oregon Psilocybin Services released its final 2025 quarterly report, providing comprehensive data on the world's first legal psilocybin therapy market. The dataset offers valuable insights for other jurisdictions considering similar therapeutic programs.
Oregon Psilocybin Program Completes 2025 Data Collection Phase
Oregon's psilocybin therapy program has completed its 2025 data collection, providing comprehensive insights into the world's first regulated psychedelic therapy framework.
Oregon Completes 2025 Psilocybin Program Data Collection
Oregon Psilocybin Services completes its 2025 data collection, providing comprehensive insights into the state's regulated psilocybin therapy program's second full year of operations.
Oregon Psilocybin Program Releases Final 2025 Data Report
Oregon Psilocybin Services released its final 2025 quarterly report, showing continued growth and safety in the state's regulated psilocybin therapy program.
Documentary Advocacy: How Psychedelic Films Shape Public Opinion
Documentary films about psychedelic therapy walk a fine line between education and advocacy, potentially influencing public opinion while omitting crucial safety information.
Documentary Explores Ketamine Therapy for First Responder PTSD
A new documentary on ketamine therapy for firefighters raises questions about balanced advocacy in psychedelic medicine while highlighting treatment potential for PTSD.
Documentary Explores Ketamine Treatment for First Responder PTSD
A documentary about ketamine therapy for firefighters with PTSD highlights both the promise and challenges of psychedelic advocacy in mainstream medicine.
Psilocybin Shows Promise for Chronic Suicidal Thoughts in Study
New research by psychiatrist Scott T. Aaronson explores psilocybin therapy for patients with chronic suicidal thoughts, showing promising safety and efficacy signals in a previously excluded high-risk population.
Psilocybin Shows Promise for Chronic Suicidal Thoughts in Study
New clinical research led by Scott T. Aaronson demonstrates psilocybin's potential for treating chronic suicidal ideation, marking the first study to focus specifically on this high-risk patient population.
Psilocybin Shows Promise for Chronic Suicidal Thoughts in Study
New research led by Scott T. Aaronson explores psilocybin therapy for patients with chronic suicidal ideation, marking a significant shift in psychedelic medicine by focusing on traditionally excluded high-risk populations.
African Psilocybin Species P. ochraceocentrata Gains Research Focus
Psilocybe ochraceocentrata, formerly classified as P. natalensis, emerges as a potent African psilocybin species with characteristics that may rival P. cubensis in research applications.
African Psilocybin Species P. ochraceocentrata Shows Promise
African psilocybin species P. ochraceocentrata shows promising potency levels comparable to P. cubensis, offering new insights for psychedelic research.
African Psilocybin Species P. ochraceocentrata Gains Recognition
Scientists have officially reclassified the African psilocybin mushroom formerly known as P. natalensis as P. ochraceocentrata, providing clearer identification for this potent species that rivals P. cubensis.
NFL Star Jordan Poyer Champions Psychedelic Healing Through Tour
NFL player Jordan Poyer launches educational tour sharing his healing journey with ayahuasca and promoting responsible psychedelic medicine awareness.
US Psychedelic Policy Surge: April 2026 Legislative Roundup
April 2026 saw major US psychedelic policy developments, including a federal executive order from President Trump and mixed state-level legislative progress. These changes could influence international psychedelic regulation and research opportunities.
US Psychedelic Policy Surge: Trump Executive Order Shapes April 2026
President Trump's April 2026 executive order on psychedelic policy, alongside state legislative activity, signals major shifts that could impact Dutch smartshop markets and international research collaboration.
US Psychedelic Policy Advances Under Trump Administration in 2026
President Trump's April 2026 executive order on psychedelics marked a significant federal policy shift as state legislatures advanced various reform bills. These developments could influence global drug policy and benefit Dutch smartshop consumers.
US Psychedelic Policy Advances as Federal Action Accelerates
April 2026 marked a turning point for US psychedelic policy with President Trump's executive order and state legislative progress creating new momentum for reform.
US Psychedelic Policy Advances Significantly in April 2026
President Trump's April 2026 executive order on psychedelic policy, combined with advancing state legislation, marks a historic shift in US drug policy reform.
US Psychedelic Policy Shifts Under Trump Administration in April 2026
President Trump's April 2026 executive order on psychedelic policy, combined with intense state legislative activity, signals major shifts in US drug regulation that could influence global trends.
Denver Psychedelic Conference Explores AI and Gray Market Trends
PsyCon Denver 2026 explored how AI, alternative wellness, and gray market products are reshaping the psychedelic industry landscape.
Denver Psychedelic Conference Explores AI and Wellness Trends
PsyCon Denver 2026 showcased how AI, alternative wellness, and gray market dynamics are reshaping the modern psychedelic industry.
PsyCon Denver 2026 Explores Future of Psychedelic Industry
PsyCon Denver 2026 explored AI integration, alternative wellness trends, and gray market challenges shaping the future of the psychedelic industry.
PsyCon Denver 2026 Explores AI and Alternative Wellness Trends
PsyCon Denver 2026 focused on AI integration, alternative wellness trends, and gray market challenges in the evolving psychedelic industry.
Denver Psychedelic Conference Explores AI and Alternative Wellness
PsyCon Denver 2026 explored how AI, alternative wellness, and gray market products are reshaping the modern psychedelic industry.
Ketamine Shows Promise for Treating Postpartum Depression
New research shows ketamine therapy may provide rapid relief for postpartum depression, offering hope for the 20% of new mothers affected by this serious condition.
Essential Safety Tips for Psychedelic Experiences in Nature
Expert guidance reveals essential safety protocols for combining psychedelic experiences with natural outdoor settings, emphasizing preparation and risk management.
Safe Psychedelic Experiences in Nature: Essential Guide
A comprehensive guide for safely combining psychedelic experiences with natural environments, covering essential preparation, safety measures, and responsible practices.
Essential Safety Guide for Psychedelic Experiences in Nature
A comprehensive safety guide for those planning psychedelic experiences in natural settings, covering preparation, risk management, and integration practices.
Decade-Long Psilocybin Study Targets Cocaine Addiction Treatment
Researcher Peter Hendricks advances a decade-long clinical trial investigating psilocybin's potential to treat cocaine addiction, offering new therapeutic possibilities.
Psilocybin Shows Promise for Cocaine Addiction Treatment Research
A decade-long clinical trial led by Peter Hendricks examines psilocybin's potential to treat cocaine addiction, representing a major advancement in psychedelic-assisted therapy research.
Trump's Psychedelics Order Sparks Mixed Industry Reactions
Trump's executive order on psychedelic medicine draws mixed reactions from industry advocates and faces prior DEA resistance, potentially influencing global psychedelic policy.
Trump's Psychedelic Executive Order Sparks Mixed Industry Reactions
Trump's executive order on psychedelic research and access has generated mixed reactions from industry leaders, with supporters praising potential progress while critics question implementation challenges.
Trump's Psychedelics Executive Order Sparks Mixed Industry Response
Trump's psychedelics executive order receives mixed reactions from industry advocates, while the DEA previously resisted Right to Try applications for psychedelic treatments.
Trump's Psychedelics Order Sparks Mixed Industry Reactions
Trump's executive order on psychedelics has generated mixed reactions from industry leaders, with supporters praising potential research acceleration while critics question practical implementation challenges.
Berkeley Exhibition Honors Psychedelic Research Pioneers Shulgins
A new Berkeley exhibition showcases the groundbreaking research archives of Ann and Sasha Shulgin, the pioneering couple behind MDMA synthesis and psychedelic chemistry.
Professional Microdosing Guides Emerge as Demand Grows
Professional microdosing facilitators are emerging to meet growing demand for structured guidance in psychedelic wellness practices. This trend is particularly relevant for Dutch consumers who have legal access to psilocybin truffles through smartshops.
Growing Demand for Professional Microdosing Support Services
Professional microdosing facilitators are emerging to meet growing demand for structured guidance and safety support in psychedelic wellness practices.
Ibogaine Advocate Discusses Trump's Psychedelics Executive Order
W. Bryan Hubbard, CEO of Americans for Ibogaine, played a key role in President Trump's psychedelics executive order, potentially influencing international policy and Dutch smartshop markets.
Ibogaine Advocate Discusses Trump's Psychedelic Executive Order
Americans for Ibogaine CEO W. Bryan Hubbard played a key role in Trump's psychedelic executive order, potentially impacting global psychedelic policy and Dutch markets.
Ibogaine Executive Order Architect Discusses Psychedelic Policy Future
W. Bryan Hubbard, CEO of Americans for Ibogaine, played a key role in orchestrating a presidential executive order on psychedelics, potentially influencing future policy developments.
Building Deeper Bonds Through Shared Psychedelic Experiences
Sharing psychedelic experiences with trusted friends creates unprecedented intimacy and lasting bonds through collective vulnerability and mutual support.
How Psilocybin Mushrooms Strengthen Bonds Between Friends
Research shows psilocybin mushrooms can deepen friendships by breaking down social barriers and enhancing empathy between trusted companions.
Bryan Johnson's DMT Trial Highlights Psychedelic Mainstream Shift
Tech entrepreneur Bryan Johnson's documented 5-MeO-DMT experience reflects psychedelics' growing acceptance in mainstream wellness and optimization circles.
Bryan Johnson's 5-MeO-DMT Trial Sparks Mainstream Psychedelic Debate
Tech entrepreneur Bryan Johnson's documented 5-MeO-DMT experience highlights tensions between optimization culture and traditional psychedelic use as these substances enter mainstream wellness discussions.
Bryan Johnson's DMT Trial Sparks Mainstream Psychedelic Debate
Tech entrepreneur Bryan Johnson's public 5-MeO-DMT experiment demonstrates how psychedelics are entering mainstream optimization culture through scientific documentation and measurement.
Psychedelic Renaissance Faces Inclusivity Challenges Worldwide
The booming psychedelic industry faces growing concerns about inclusivity and access, as traditional communities and marginalized groups risk being left behind in the rush toward commercialization.
MAPS Founder Addresses Gaza Controversy Amid Psychedelic Research
MAPS founder Rick Doblin addressed protesters questioning the organization's Israel connections, while new research explores psilocybin's potential for weight loss treatment.
Gaza Conflict Protests Disrupt Major Psychedelic Conference in SF
Protesters disrupted a major psychedelic conference in San Francisco over Gaza conflict, sparking debates about political engagement within the consciousness community.
Gaza Protests Disrupt Major Psychedelic Conference in San Francisco
Protesters disrupted the Psychedelic Culture Conference in San Francisco, confronting MAPS founder Rick Doblin about Gaza and highlighting tensions between psychedelic advocacy and political activism.
FDA Grants Priority Review Status to Three Psychedelic Companies
The FDA has awarded Priority Review Vouchers to Otsuka, Compass, and Usona, accelerating the regulatory pathway for psychedelic therapies and signaling growing institutional acceptance of these innovative mental health treatments.
FDA Grants Fast-Track Review Status to Three Psychedelic Companies
The FDA has granted Priority Review Vouchers to Otsuka, Compass, and Usona, fast-tracking psychedelic medicine development and potentially reshaping mental health treatment.
FDA Grants Fast-Track Review Status to Three Psychedelic Companies
The FDA has granted Priority Review Vouchers to Otsuka, Compass Pathways, and Usona Institute, accelerating the regulatory pathway for psychedelic medicines and marking a significant milestone for the industry.
FDA Grants Fast-Track Status to Three Major Psychedelic Companies
The FDA has granted Priority Review Vouchers to Otsuka, Compass Pathways, and Usona Institute, accelerating the regulatory timeline for their psychedelic therapy developments.
Psychedelic Research Acceleration Faces Complex Implementation
New federal efforts to speed up psychedelic research face significant challenges including funding gaps, ethical concerns, and regulatory hurdles that may slow implementation despite political support.
Psychedelic Rights Activists Rally in NYC and San Francisco
Psychedelic rights activists organized coordinated demonstrations in Manhattan and San Francisco, advocating for cognitive liberty and expanded access to psychedelic substances.
Psychedelic Rights Advocates Rally in NYC and San Francisco
Psychedelic advocates organized simultaneous events in Manhattan and San Francisco, marching for cognitive liberty and challenging restrictive drug policies.
Psychedelic Advocates Rally for Cognitive Liberty Across US Cities
Psychedelic advocates organized coordinated demonstrations in Manhattan and San Francisco, promoting cognitive liberty and therapeutic access rights.
Psychedelic Rights Activists Rally Across US for Cognitive Freedom
Psychedelic rights advocates organized coordinated demonstrations in Manhattan and San Francisco, demanding recognition of cognitive liberty as a fundamental human right.
Psychedelic Therapy Transforms End-of-Life Care Practices
Specialized retreats are combining psychedelic therapy with end-of-life care, helping terminal patients overcome death anxiety and find peace through guided consciousness exploration.
Psychedelic Retreats Help People Prepare for Death Consciously
Specialized retreats combine psychedelic therapy with end-of-life care, helping participants develop conscious approaches to mortality through guided therapeutic experiences.
Psychedelic Therapy Transforms End-of-Life Care Approaches
Psychedelic-assisted therapy retreats are revolutionizing end-of-life care by helping individuals confront mortality fears and discover deeper meaning in both dying and living.
Trump's Psychedelic Research Order Sparks Industry Optimism
President Trump's executive order to accelerate psychedelic research has sparked optimism across the industry, with potential implications for Dutch smartshop markets and international regulatory frameworks.
Trump's Psychedelic Executive Order Sparks Industry Optimism
President Trump's executive order accelerating psychedelic research receives positive industry response, with potential implications for Dutch smartshop markets.
Trump Psychedelics Order Sparks Industry Optimism Worldwide
President Trump's executive order accelerating psychedelic research has generated positive industry reactions, potentially influencing European markets and Dutch smartshop regulations.
Trump's Psychedelic Research Order Sparks Industry Optimism
President Trump's executive order accelerating psychedelic research has generated positive reactions across the industry, with implications for global therapeutic development and Dutch smartshop markets.
Trump Psychedelics Order Sparks Mixed Industry Response
President Trump's executive order on psychedelic research acceleration receives largely positive industry response, with potential implications for Dutch smartshop markets and international collaboration.
Psychedelic Therapy Risks: Expert Warns of Healing's Dark Side
Mental health experts highlight concerning power dynamics and retraumatization risks in psychedelic therapy settings. The discussion emphasizes need for stronger safety protocols as treatment gains mainstream acceptance.
Trump Executive Order Accelerates Psychedelic Therapy Research
President Trump signed an executive order to accelerate psychedelic therapy research, particularly ibogaine treatment for veterans with mental health conditions.
US Executive Order Accelerates Psychedelic Therapy Research
President Trump signed an executive order to accelerate psychedelic therapy research, particularly ibogaine treatment for veterans' mental health conditions.
Trump Accelerates Psychedelic Therapy Research for Veterans
President Trump signs executive order to accelerate psychedelic therapy research, particularly ibogaine treatment for veterans with mental health challenges.
US President Accelerates Psychedelic Therapy Research for Veterans
A new US executive order aims to fast-track psychedelic therapy research, particularly ibogaine treatment for veterans, potentially influencing global regulatory approaches to alternative mental health treatments.
Trump Accelerates Psychedelic Therapy Research for Veterans
President Trump signed an executive order to fast-track psychedelic research, particularly ibogaine therapy for veterans' mental health treatment.
US Executive Order Accelerates Psychedelic Therapy Research
President Trump signs executive order to accelerate psychedelic therapy research, particularly ibogaine treatment for veterans with mental health conditions.
Mobile Betting Apps Face Regulatory Challenges in Europe
Mobile betting apps face complex regulatory challenges across Europe, with the Netherlands maintaining strict licensing requirements that affect app store availability.
Mobile Betting Apps Face Regulatory Hurdles in European Markets
Mobile betting applications face complex regulatory approval processes for app store distribution, particularly in European markets with evolving gambling legislation.
Online Betting Registration Guide: What Dutch Users Should Know
A comprehensive guide examining online betting platform registration processes and the important legal considerations for Dutch consumers under current gambling regulations.
Online Betting Registration Guide: Safety Tips for Dutch Users
Dutch consumers should prioritize licensed operators when considering online betting platforms, as unlicensed alternatives pose significant legal and financial risks.
Online Gaming Apps: Security and Features in Digital Platforms
Modern gaming applications offer sophisticated features and security measures, but Dutch consumers should prioritize platforms with proper licensing and robust user protection.
Mobile Betting Apps Gain Popularity in European Markets
Mobile betting and gaming applications are gaining significant traction in European markets, offering enhanced security features and user-friendly interfaces for on-the-go entertainment.
Key Insights from Psychedelic Culture 2026 Conference Revealed
The Psychedelic Culture 2026 conference revealed major advances in ketamine therapy, DMT laser technology, and plant medicine integration practices.
US Psychedelics Executive Order Signals Policy Shift
A new US executive order acknowledges psychedelic research for mental health treatment, signaling a major federal policy shift that could impact global markets including Dutch smartshops.
US Executive Order Signals Major Shift in Psychedelics Policy
A new US executive order marks a historic shift toward federal acceptance of psychedelic medicine, potentially impacting global markets and research collaboration.
US Executive Order on Psychedelics: What It Means for Global Markets
A new US executive order on psychedelics signals a major policy shift toward therapeutic research, with significant implications for Dutch smartshops and European markets.
Trump Administration Advances Psychedelic Research Through New Order
The Trump administration has signed an executive order to accelerate psychedelic research and improve access to these treatments, marking a significant shift in US federal policy toward therapeutic psychedelics.
US Psychedelic Task Forces: Bridging Policy Gaps in Therapy Reform
US state task forces examining psychedelic therapy regulation face challenges bridging the gap between advocate expectations and legislative caution.
US Psychedelic Task Forces: Bridging Policy Gaps in Therapy Reform
US state psychedelic task forces reveal significant gaps between advocacy goals and legislative realities in implementing therapeutic reform.
US Psychedelic Task Forces: Progress or Political Theater?
US state task forces examining psychedelic regulation face challenges translating advocacy goals into workable legislation, highlighting the gap between scientific evidence and political action.
US Psychedelic Task Forces: Progress or Political Theater?
US state psychedelic task forces show promise for reform but reveal significant gaps between advocate expectations and legislative reality.
US State Psychedelic Task Forces: Progress or Political Theater?
US state psychedelic task forces face challenges bridging the gap between advocacy goals and legislative reality, offering lessons for international drug policy development.
US Psychedelic Task Forces: Bridging Policy Gaps or Creating Delays?
US state psychedelic task forces show promise for policy reform but face challenges bridging the gap between advocate expectations and legislative reality.
US Psychedelic Task Forces Show Mixed Results for Policy Reform
US state psychedelic task forces face challenges balancing advocate demands with legislative caution, offering lessons for global policy reform including implications for Dutch smartshop regulations.
US State Psychedelic Task Forces Face Implementation Challenges
US state psychedelic task forces struggle to balance advocacy goals with political realities, revealing implementation challenges for therapeutic regulation.
US Psychedelic Task Forces Show Mixed Results for Policy Reform
US state psychedelic task forces reveal significant gaps between advocacy goals and legislative reality, offering mixed results for policy reform efforts.
DMT Laser Study Reignites Simulation Theory Debate Among Scientists
New research combining DMT and laser technology produces intriguing results that some interpret as evidence for simulation theory, though neuroscientists remain skeptical.
Ibogaine Gains Political Momentum as Advocates Target US Leadership
Former Texas Governor Rick Perry and advocates are pushing ibogaine therapy into mainstream political discourse, leveraging media attention to promote the psychedelic compound's addiction treatment potential.
Ibogaine Advocates Target Trump Administration Through Rogan Platform
Former Governor Rick Perry and advocates are using Joe Rogan's platform to influence Trump administration policy on ibogaine, while Compass Pathways launches training grants for psychedelic therapists.
Psychedelic Investment Drops to $348M in Q1 2026 Despite Growth
Psychedelic sector funding reached $348M in Q1 2026 across 11 deals, with Compass Pathways securing the majority of investments as the industry matures.
Top Global EDM Festivals Every Electronic Music Fan Should Know
A comprehensive guide to the world's premier electronic dance music festivals, exploring destinations that offer unique cultural experiences for international EDM enthusiasts.
Cambridge University Launches Major Psychedelic Research Initiative
Cambridge University has launched a major psychedelic research program, marking a significant milestone in academic acceptance of psychedelic science and its therapeutic potential.
Psychedelic Culture Challenges Drug Laws and Authority Structures
A growing movement of psychedelic advocates is using creative methods to challenge drug prohibition and promote consciousness exploration.
Major Psychedelic Research Conferences Draw Global Experts to US
Over 200 psychedelic industry professionals gathered in New Orleans for dual conferences focusing on therapeutic development and research advances.
Therapist Calls for Consciousness Shift Away from Digital Division
Therapist Charles Wininger challenges society to reject digital-induced hatred and seek guidance from inner wisdom rather than divisive media.
Therapist Calls for Cultural Shift Away from Digital Division
Therapist Charles Wininger challenges society to reject digital division and seek guidance from higher consciousness rather than divisive media.
Therapist Calls for Cultural Shift Away from Digital Division
Therapist Charles Wininger challenges millions to reject media-driven hatred and political vitriol, advocating for guidance from inner wisdom over divisive digital influences.
Psychedelic Patent Landscape Shows Major Growth in Early 2026
Q1 2026 data reveals unprecedented growth in psychedelic patent applications and grants, signaling market maturation that could reshape Dutch smartshop operations and consumer access.
Psychedelic Integration Practices Gain Focus in Healthcare
Healthcare professionals are increasingly focusing on psychedelic integration practices as a crucial component of effective therapy, with new training programs and research-backed methods emerging to support lasting therapeutic outcomes.
US Psychedelic Reform Hits Record High with 100+ Bills in 2026
March 2026 saw 11 new psychedelic bills across 7 US jurisdictions, bringing the total to over 100 bills in 35 states. This represents the most significant wave of psychedelic policy reform in American history.
Home Cultivation Key to True Psychedelic Reform, Experts Argue
Experts warn that psychedelic reform without home cultivation rights may create corporate monopolies rather than true therapeutic access.
Psychedelic Industry Launches Quarterly Analysis Format in 2026
Psychedelic Alpha launches comprehensive quarterly briefings to track industry developments across drug development, policy, and research sectors in 2026.
Global Psychedelic Festivals: A Guide to Transformative Events
A comprehensive guide to the world's premier psychedelic festivals, exploring how these transformative gatherings combine music, art, and consciousness exploration.
Easter Psychedelic Celebrations Rise Among Dutch Consumers
Dutch consumers are increasingly turning to legal psychedelic substances available through smartshops to celebrate Easter themes of renewal and spiritual awakening. This trend reflects a broader cultural shift toward personalized spirituality backed by emerging scientific research.
Danish Researcher Explores Brain Mechanisms Behind Psychedelic Effects
Danish neuroscientist Gitte Moos Knudsen's research reveals how serotonin systems and environmental factors shape psychedelic experiences in the brain.
Robin Carhart-Harris Maps the Mind Using Psychedelic Research
British neuroscientist Robin Carhart-Harris uses advanced brain imaging to study how psychedelics affect consciousness. His research provides scientific validation for the therapeutic potential of substances legally available in Dutch smartshops.
German Psilocybin Study Shows Mixed Results for Depression
A major German clinical trial found psilocybin no more effective than placebo for treatment-resistant depression, challenging expectations about psychedelic therapy.
Otsuka Pharmaceuticals Acquires Psychedelic Firm for $1.23B
Otsuka Holdings acquires psychedelic medicine developer Transcend Therapeutics for $1.23 billion, marking a major pharmaceutical investment in methylone-based mental health treatments.
Billionaire Takeover of Lykos Reshapes MDMA Therapy Future
Billionaire investors are reshaping MDMA therapy research through a major corporate takeover of Lykos Therapeutics. This transformation could significantly impact European psychedelic access and regulatory approaches.
10 Mind-Bending Destinations for Psychedelic Experiences Worldwide
From spiral museums to Northern Lights, discover the world's most extraordinary destinations for psychedelic experiences. Safety and legal considerations included for responsible exploration.
US Congress Proposes VA Office for Psychedelic Therapies
US Congress introduces legislation to create a Veterans Affairs office dedicated to psychedelic therapies, marking the fourth related bill this term.
US Congress Proposes VA Office for Psychedelic Therapeutics
US Congress introduces fourth psychedelics bill this term, proposing a VA Office of Novel Therapeutics to coordinate psychedelic medicine research and treatment for veterans.
US Veterans May Get Dedicated Psychedelic Treatment Office
New US legislation proposes creating a federal office for psychedelic therapies within Veterans Affairs, marking the fourth related bill this congressional term.
US Veterans May Get Access to Psychedelic Therapy Under New Bill
New US legislation proposes establishing a Veterans Affairs Office of Novel Therapeutics to explore psychedelic treatments for military mental health conditions.
US Veterans May Get Access to Psychedelic Therapy Under New Bill
New US legislation proposes establishing a VA Office of Novel Therapeutics to explore psychedelic treatments for veterans, marking the fourth psychedelics-related bill in Congress this term.
US Veterans May Get Dedicated Psychedelic Therapy Office Under New Bill
New US legislation proposes creating a dedicated Veterans Affairs office for psychedelic therapies, marking the fourth psychedelics-related bill in Congress this term.
Psychiatrist Warns Approval Won't Fix Psychedelic Care Challenges
Cleveland Clinic psychiatrist Dr. Brian Barnett warns that regulatory approval alone won't solve the fundamental challenges of scaling psychedelic medicine within existing healthcare systems.
US Psychedelic Approvals Progress Despite Political Uncertainty
Despite political uncertainty, multiple FDA approvals for psychedelic therapies remain on track while advocacy groups adapt to changing election year dynamics.
Leading Psychiatrist Champions Data-Driven Psychedelic Research
Dr. Charles Nemeroff leads groundbreaking psychedelic research at Dell Medical School, emphasizing data-driven approaches to substances like ibogaine for treating depression and addiction.
US Government Backs 5-MeO-DMT Research in Psychedelic Breakthrough
The US government accelerates support for 5-MeO-DMT clinical trials, marking a significant shift in federal psychedelic research policy with implications for global therapeutic development.
Mixed Results in Psychedelic Drug Trials Show Industry Challenges
Recent clinical trials show mixed results for psychedelic therapeutics, with Helus Pharma reporting unclear outcomes for their DMT analog while AtaiBeckley advances multiple programs.
AtaiBeckley Seeks Partnership for 5-MeO-DMT Depression Treatment
AtaiBeckley is in advanced partnership talks for its intranasal 5-MeO-DMT depression treatment, with major pharma companies showing increased interest following recent industry consolidation.
University Study Explores Psilocybin's Role in Boosting Creativity
University of Texas researchers are conducting the first modern study on psilocybin's ability to enhance creativity and problem-solving, potentially validating experiences reported by Dutch smartshop customers.
Major Study Finds Microdosing Effects Last Only Hours, Not Days
New research involving 1,435 participants reveals that microdosing benefits fade within hours rather than lasting for days, challenging common assumptions about extended effects.
Quarter of Americans Back Medical Psilocybin Use, RAND Study Finds
New RAND Corporation research shows 25% of Americans support legal psilocybin use, with therapeutic applications driving public acceptance over recreational interests.
Gender Differences in Psychedelic Effects Revealed in New Research
New research reveals significant differences between male and female responses to psychedelic substances, potentially reshaping therapeutic applications and consumer understanding.
Scientists Confirm Psilacetin Functions as Psilocin Prodrug
New research provides first scientific proof that psilacetin functions as a prodrug of psilocin, validating a 25-year-old hypothesis about synthetic psilocybin analogs.
New Research Shows Chemical Tweaks Transform Inactive Compounds
New research reveals how minor chemical modifications to norpsilocin can dramatically alter its pharmacological properties, highlighting the importance of monoalkyl tryptamine derivatives.
New Research Uncovers Key Insights Into Psilocybin Chemistry
New research reveals how minor chemical modifications to norpsilocin can dramatically alter pharmacological effects, providing crucial insights into psilocybin chemistry.
Psilocybin Companies Lead Therapeutic Research Revolution
Leading biotechnology companies are systematically analyzing magic mushroom compounds to develop standardized therapeutic medicines, transforming traditional cultivation into pharmaceutical-grade research.
Psilocybin Companies Lead Therapeutic Medicine Development
Leading psilocybin companies are analyzing magic mushroom compounds to develop standardized therapeutic medicines, potentially impacting Dutch smartshop markets.